Otsuka coughs up $3.5bn for Avanir
This article was originally published in Scrip
Executive Summary
Japanese firm Otsuka Pharmaceutical has agreed to acquire Avanir Pharmaceuticals, the California-based company that sells a reformulated cough and heart medicine combination to treat uncontrolled laughing and crying, for $3.5bn.